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Abstract
Rationale The dopamine D2 receptor (D2R) couples to inhib-
itory Gi/o proteins and is targeted by antipsychotic and
antiparkinsonian drugs. Beta-arrestin2 binds to the intracellu-
lar regions of the agonist-occupied D2R to terminate G protein
activation and promote internalization, but also to initiate
downstream signaling cascades which have been implicated
in psychosis. Functional magnetic resonance imaging (fMRI)
has proven valuable for measuring dopamine receptor-
mediated changes in neuronal activity, and might enable
beta-arrestin2 function to be studied in vivo.
Objectives The present study examined fMRI blood oxygen-
ation level dependent (BOLD) signal changes elicited by a
dopamine agonist in wild-type (WT) and beta-arrestin2
knockout (KO) mice, to investigate whether genetic deletion
of beta-arrestin2 prolongs or otherwise modifies D2R-depen-
dent responses.
Methods fMRI BOLD data were acquired on a 9.4 T system.
During scans, animals received 0.2 mg/kg apomorphine, i.v.
In a subset of experiments, animals were pretreated with 2 mg/
kg of the D2R antagonist, eticlopride.
Results Following apomorphine administration, BOLD signal
decreases were observed in caudate/putamen of WT and KO
animals. The time course of response decay in caudate/
putamen was significantly slower in KO vs. WT animals. In
cingulate cortex, an initial BOLD signal decrease was follow-
ed by a positive response component in WT but not in KO
animals. Eticlopride pretreatment significantly reduced
apomorphine-induced BOLD signal changes.
Conclusions The prolonged striatal response decay rates in KO
animals might reflect impaired D2R desensitization, consistent
with the known function of beta-arrestin2. Furthermore, the
apomorphine-induced positive response component in cingu-
late cortex may depend on beta-arrestin2 signaling downstream
of D2R.
Keywords Arrestin3 . Dopamine . Dopamine receptor .
Dopamine agents . Eticlopride
Introduction
Dopamine signaling is crucially involved in a multitude of phys-
iological brain functions, such as motor program selection,
goal-directed behavior, and endocrine homeostasis. Dopamine
receptors, in particular, the dopamine D2 receptor (D2R) consti-
tute important drug targets for treatment of neuropsychiatric,
neurological, and neuroendocrine disorders, such as
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Parkinson’s disease, schizophrenia, and hyperprolactinemia
(Beaulieu and Gainetdinov 2011). Dopamine receptors, which
belong to the super-family of G-protein coupled receptors
(GPCRs), are known to signal via several downstream pathways,
which include the classical G protein-pathway, and the more
recently described arrestin pathway. Themain postsynaptic effec-
tor mechanism of dopamine in the striatum has long been con-
sidered to be themodulation of adenylate cyclase via the coupling
of D2-like (D2R, D3R, D4R) and D1-like (D1R, D5R) receptors to
inhibitory Gi/o- and stimulatory Gs proteins, respectively.
However, the important role of the arrestin pathway in dopa-
minergic signaling has become increasingly apparent during the
past decade. Arrestins are a family of proteins known to bind
GPCRs following their activation by agonist, thus blocking fur-
ther receptor-G protein interactions and initiating GPCR inter-
nalization (Claing et al 2002). Whereas, the role of arrestins in
receptor desensitization and internalization is well-established,
recent studies have demonstrated that arrestins can also scaffold
other signaling proteins, including protein phosphatase 2A
(PP2A) and Akt, a protein kinase which has been genetically
linked to psychosis risk (Emamian et al. 2004). Beta-arrestin2
(also known as arrestin3) has been specifically implicated as the
arrestin isoform regulating D2R internalization as well as down-
stream signaling cascades (Beaulieu et al. 2005; Peterson et al.
2015; Skinbjerg et al. 2009). Notably, beta-arrestin2 knock out
(KO) mice show a reduced locomotor response to the direct-
acting dopamine agonist, apomorphine, and the dopamine-
releasing agent, amphetamine (Beaulieu et al. 2005).
All clinically used antipsychotics antagonize beta-arrestin2
recruitment to the D2R, suggesting that this mechanism might
be relevant for their therapeutic activity (Klewe et al. 2008;
Masri et al. 2008). It has been proposed that the clinical ben-
efits of antipsychotics are mediated mainly via inhibition (or
in the case of aripiprazole, partial agonism) of the beta-
arrestin2 pathway, whereas attenuation of G protein activation
would be responsible for extrapyramidal side effects.
Accordingly, efforts are underway to develop D2R ligands
which specifically modulate arrestin signaling (Allen et al.
2011; Park et al. 2016). Novel data from the Caron lab (Urs
et al. 2016) suggest that ligands such as UNC9994 (Allen et al.
2011), which are partial agonists at the arrestin pathway, exert
antipsychotic-like actions in rodent models of schizophrenia
by activating the D2R-arrestin pathway preferentially in corti-
cal, as compared to striatal regions, due to the higher expres-
sion of beta-arrestin2 in cortex. Taken together, the present
evidence suggests that the arrestin pathway is an important
aspect of dopaminergic signaling and that dysregulation of
this pathway might play a key role in states of altered dopa-
mine signaling, such as schizophrenia (Freyberg et al. 2010).
A measure of beta-arrestin2 activity which could be obtained
in vivo might thus be useful in translational studies.
Functional magnetic resonance imaging (fMRI) is an attrac-
tive, non-invasive method for measuring neuronal activity in
the living brain, and has proven valuable for investigating do-
paminergic signaling in a variety of contexts, including cogni-
tive and psychiatric studies in human subjects and investiga-
tions of receptor function as well as drug development in ex-
perimental animals (see, e.g., Booij and van Amelsvoort 2012;
Bruns et al. 2015; Cools and D'Esposito 2011; Knutson and
Gibbs 2007; Mandeville et al. 2014). Beta-arrestin2 KO mice
have previously been used to characterize the contribution of
beta-arrestin2 to dopamine-dependent behaviors, as well as to
study the effects of D2R internalization on PET radioligand
binding following amphetamine administration (Beaulieu
et al. 2005; Skinbjerg et al. 2010). However, the role of beta-
arrestin2 in brain hemodynamic responses to dopaminergic
challenges has not yet been explored. Hence, the present study
was designed to examine blood oxygenation level dependent
(BOLD) fMRI responses to the dopamine agonist, apomor-
phine, in caudate/putamen (CPu) and cingulate cortex (Cg) of
wild-type (WT) and beta-arrestin2 KO mice.
Materials and methods
Animals
Male beta-arrestin2 KO mice (Bohn et al. 1999) and age-
matched C57BL/6 J WT counterparts were purchased from
the Jackson Laboratory (Bar Harbor, ME), and were between
3 and 6 months of age when used in experiments.
Drugs
R-(−)-Apomorphine hydrochloride was purchased from
Sigma-Aldrich (St. Louis, MO), S-(−)-eticlopride from
Abcam chemicals (Cambridge, UK), and UNC9994 was
custom-synthesized by Axon Medchem B.V. (Groningen,
the Netherlands). Eticlopride was dissolved in saline, apomor-
phine in saline supplemented with 1 mM ascorbic acid
(Merck, Darmstadt, Germany; pH 7.4 with NaOH), and
UNC9994 was dissolved in saline supplemented with 15%
w/v (2-hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich).
Autoradiography
Mice were sacrificed at 6 months of age, and their brains were
immediately removed and fresh-frozen on powdered dry ice.
Brains were sectioned at 20 μm on a cryostat and
thaw-mounted onto Fisher Superfrost Plus slides (Thermo
Fisher Scientific, Waltham, MA), with 12 sets of 12 sections
per slide taken from the rostral through caudal striatum, cor-
responding approximately to Bregma +2.0 to −1.0 mm
(Paxinos and Franklin 2001). Slides were stored at −80 °C
until processing for autoradiography. [3H]SCH23390 (85 Ci/
mmol), [3H]raclopride (76 Ci/mmol), and [3H]WIN35428
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(76 Ci/mmol) were purchased from Perkin Elmer Life
Sciences (Boston, MA). [3H]dihydrotetrabenazine
([3H]DTBZ; 20 Ci/mmol) was purchased from American
Radiolabeled Chemicals (St. Louis, MO).
All sections were pre-incubated for 20 min in binding buffer
(50 mM Tris, pH 7.4, 25 °C, containing 120 mM NaCl,
5 mM KCl) to remove endogenous receptor ligands. Following
incubationwith the respective radioligand in an open staining jar,
slides were then rinsed five times at 1 min intervals with ice-cold
buffer, and subsequently air dried and made conductive by coat-
ing the free side with a copper foil tape. The radioligand concen-
trations used were [3H]SCH23390, 3.5 nM; [3H]raclopride,
2.9 nM; [3H]WIN35428, 2.2 nM; [3H]DTBZ, 5.8 nM. Slides
were then placed in a gas chamber containing a mixture of argon
and triethylamine (Sigma-Aldrich) as part of a gaseous detector
apparatus; the Beta Imager 2000Z Digital Beta Imaging System
(Biospace Lab, Nesles la Vallée, France). After the gas was well
mixed and a homogenous state was reached, further exposure for
12 h yielded high-quality images. A [3H]Microscale (American
Radiolabeled Chemicals) was counted simultaneously as a ref-
erence for quantitative radioactivity analysis.
Data analysis was performed using the program Beta-Vision
Plus (Biospace Lab). Using neuroanatomical landmarks
(Paxinos and Franklin 2001), bilateral regions of interest
(ROIs) were drawn freehand along the border of the entire
striatum of serial sections from each individual mouse brain
to define the representative striatal binding densities. Data were
linearly fitted to a standard slope which was used for calibra-
tion, thereby converting counts per minute per mm2 into nCi
per mg tissue. Subsequently, the radioligand binding densities
were calculated using the specific activity of each radioligand as
previously described (Xu et al. 2010). Nonspecific binding was
determined by incubating slides with radioligand in the presence
of an excess concentration of a cold competitor; 1 μM (+)-
butaclamol ([3H]SCH23390), 1 μM S-(−)-eticlopride
([3H]Raclopride), 1 μM nomifensine ([3H]Win35428), and
1 μM S-(−)-tetrabenazine ([3H]DTBZ), respectively.
Animal preparation for fMRI experiments
Animals were anesthetized with isoflurane (4% for induction,
2% for endotracheal intubation and during set-up on the ani-
mal cradle) in a 20% O2/80% air mixture. For reproducible
positioning, the head of the animals was fixed using stereo-
tactic ear bars. Ophthalmic ointment was applied to the eyes.
A rectal temperature probe served to keep the animal at
36.0 ± 0.5 °C by means of a warm-water circuit as part of
the animal cradle (Bruker Biospin GmbH, Ettlingen,
Germany). After intubation and positioning on the cradle,
mice were maintained under 1.5% isoflurane and artificial
ventilation using a small animal ventilator (MRI-1; CWE
Inc., Ardmore, PA), with a 20% O2/80% air mixture at a rate
of 80 breaths/min, with a respiration cycle of 25% inhalation,
75% exhalation, and an inspiration volume of 1.8 ml/min.
Pharmaceutical drugs were delivered via a cannula inserted
into the tail vein (i.v.), or the nape of the animal (s.c.).
0.7 mg/kg pancuronium bromide (a neuromuscular blocking
agent; Sigma-Aldrich), was administered i.v. before starting
the fMRI experiments. In a subset of experiments, animals
received 2 mg/kg eticlopride s.c. before starting fMRI data
acquisition and 25 min prior to apomorphine administration.
fMRI
Eleven WT and 15 beta-arrestin2 KO mice were imaged on a
9.4 T Bruker BioSpec 94/30 MR system (Bruker BioSpin)
using a four-element cryogenic phased array surface receiver
coil together with a linearly polarized room temperature vol-
ume resonator for transmission. Sixteen contiguous 0.5-mm
thick slices were acquired with the most rostral slice at
Bregma +3.5, with reference to a stereotaxic mouse brain atlas
(Paxinos and Franklin 2001). An anatomical reference scan
was obtained using a T2-weighted rapid acquisition with re-
laxation enhancement (RARE) sequence: field of view
(FOV) = 23 . 66 × 14 mm2 , ma t r i x d imen s i on
(MD) = 338 × 200, resulting in an in-plane voxel dimension
of 70 × 70 μm, repetition time (TR) = 3500 ms, echo time
(TE) = 13 ms, effective echo time (TEeff) = 52 ms, RARE
factor = 8, number of averages (NA) = 2. BOLD fMRI data
was acquired with 1-s time resolution using a gradient-echo
echo-planar imaging (GE-EPI) sequence: FOV = 16 × 7 mm2,
MD = 80 × 35, yielding an in-plane voxel dimension of
200 × 200 μm, TR = 1000 ms, TE = 12 ms, flip angle
(FA) = 60°, NA = 1. Before starting the fMRI sequence, local
field homogeneity had been improved in the area of interest
using previously acquired field maps. Each BOLD fMRI scan
session lasted 40 min (2400 repetitions), out of which 10 min
of baseline were recorded before drug administration. During
scans, drugs were administered using an infusion pump
(Harvard Apparatus, Holliston,MA) connected to an i.v. (apo-
morphine, UNC9994) or s.c. (eticlopride) cannula.
fMRI data analysis
The first 300 volumes (i.e., 300 s of the 600 s (10 min) lasting
baseline) of each data set were discarded to account of the T1
relaxation and for equilibration purposes. Drifts were removed
from the BOLD signal using linear regression with the
Statistical Parametric Mapping (SPM; http://www.fil.ion.ucl.
ac.uk/spm/) function spm_filter (cut-off at 2100 repetitions =
whole time series, thus corresponds to a linear detrend) and
converted into percent relative to baseline.
As the concentration-time-curve for apomorphine and
hence the response-model-function per defined brain voxel/
region is unknown, a model-free visualization approach was
chosen. Color-coded maps were generated with AFNI (http://
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afni.nimh.nih.gov/) to visualize the voxel-wise integral of the
BOLD signal curve over the intervals 300 s (time point of
apomorphine injection) to 600 s, 600 to 900 s, and 600 to
2100 s.
Time courses of BOLD signal changes were analyzed
using the freeware plugin, Aedes (aedes.uef.fi), running
under MATLAB (The MathWorks, Natick, MA), to draw
ROIs for CPu and Cg with guidance of a stereotaxic mouse
brain atlas (Paxinos and Franklin 2001). For visualization,
time courses of BOLD signal changes extracted from the
drawn ROIs were smoothed using a 5-s moving average.
Fitting of monoexponential functions to time course data, in
order to quantify response decay rates, was done in Matlab.
Graph plotting was done in MS Excel (Microsoft, Redmond,
WA), Origin (OriginLab, Northampton, MA), and GraphPad
Prism (GraphPad Software, Inc., La Jolla, CA). Statistical
analyses (Two-way ANOVA with Bonferroni-corrected
pairwise comparisons, two-way repeated measures ANOVA,
or Student’s t-test) were performed on BOLD signal data, to
test the effects of genotype and treatment, and interactions
between them, on the BOLD response to apomorphine in
the respective ROIs, as described in the results.
Measurement of systemic physiological parameters
To test the extent of possible effects that the administered dose
of apomorphine exerts on systemic physiological variables,
heart rate (beats per minute; bpm), O2 saturation (in %), and
pulse distention (in μm) were measured using a pulse oxime-
ter (MouseOx; Starr Life Sciences Corp., Oakmont, PA), with
the optical sensor attached to the shaved flank of the mouse.
The animal was anesthetized, intubated, and ventilated, and
apomorphine was administered i.v. in the same way as during
the fMRI scan protocol.
Results
Autoradiography
Quantitative autoradiography performed on coronal tissue
sections through striata from WT and beta-arrestin2 KO mice
using tritiated ligands for D1R, D2/3R, dopamine transporter
(DAT), and vesicular monoamine transporter-2 (VMAT2) re-
vealed no significant differences in average binding densities
between the genotypes for all four radioligands (Fig. 1).
fMRI
For fMRI data analysis, ROIs were drawn for CPu and Cg
(Fig. 2). Following i.v. administration of 0.2 mg/kg apomor-
phine, BOLD signal decreases were observed in CPu and Cg
of WT and KO animals (Fig. 3 upper panel; Fig. 4a). During
the first 5 min post-apomorphine, the mean BOLD change
was −1.29 ± 0.28% (WT) and −1.62 ± 0.32% (KO) in CPu,
and −0.34 ± 0.21% (WT) and −0.62 ± 0.24 (KO) in Cg
(Fig. 4b). No obvious differences were detected between the
genotypes neither for CPu nor for Cg, which is also reflected
by the color-coded maps for BOLD signal change integrals of
300 to 600 s (i.e., up to 5 min post-apomorphine, Fig. 3 upper
panel). After reaching a negative peak, the BOLD signal am-
plitude returned towards baseline. The mean BOLD signal
change (relative to baseline) between 5 and 30 min after apo-
morphine injection was −0.46 ± 0.08% (WT) and
−0.61 ± 0.14% (KO) in CPu (Fig. 4b). In Cg, the initial
BOLD signal decrease during the first 5 min was followed
by a positive response component in WT but not in KO ani-
mals (Fig. 4a). Between 5 and 30 min post-apomorphine, the
mean BOLD signal change in Cg was 0.31 ± 0.14% (WT) and
−0.14 ± 0.14% (KO), respectively (Fig. 4b). Red-colored re-
gions on color-coded maps reflect increased and positive in-
tegral values in WT Cg compared to KO Cg for intervals of
600 to 2100 s (i.e., 5 to 30 min post-apomorphine), while as
noted above, BOLD signal changes in CPu were similar be-
tween WT and KO during that interval (Fig. 3 lower panel).
Pretreatment with eticlopride virtually abolished
apomorphine-induced BOLD signal changes in both CPu
and Cg (Fig. 4a).
There was a significant main effect of eticlopride pretreat-
ment, but not of genotype, nor any interaction between geno-
type and drug treatment, during the first 5 and the last 25 min
in CPu and during the first 5 min in Cg, (Two-way ANOVA;
F(1, 44) = 31.59, p < 0.001; F(1, 44) = 18.12, p < 0.001; F(1,
44) = 14.43, p < 0.001, for the main effect of eticlopride pre-
treatment in CPu during first 5 and last 25 min, and in Cg
during the first 5 min, respectively). During the last 25 min
in Cg, there was a significant interaction between the effects of
genotype and drug treatment (Two-way ANOVA; F(1,
44) = 4.83, p = 0.033), but no significant main effects of ge-
notype or drug treatment. Pairwise comparisons revealed a
significant difference between the effects of apomorphine,
when administered alone, in WT compared to KO mice in
Cg during the last 25 min (p < 0.05, with Bonferroni correc-
tion; Fig. 4b), but not during the first 5 min, nor during either
interval in CPu. We also performed two-way repeated mea-
sures ANOVAs with time and genotype as factors, comparing
the entire 35-min BOLD time courses with 1-min sampling
forWTand KOmice receiving apomorphine alone, and found
a significant effect of genotype in Cg (F(1, 816) = 4.48,
p = 0.045), but not in CPu (F(1, 816) = 0.56, p = 0.462).
I.v. administration of vehicle (saline + ascorbic acid or saline +
[2-hydroxypropyl]-β-cyclodextrin), or s.c. administration of
2 mg/kg eticlopride produced minor deviations of the BOLD
signal from baseline (Fig. 4c; Supplementary Fig. 1). Vehicle
induced positive changes in CPu and Cg, whereas eticlopride
induced a slight BOLD signal decrease in CPu, and an increase
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in Cg. The beta-arrestin2-biased D2R ligand, UNC9994, was
also tested inKO andWTmice. UNC9994 elicited BOLD signal
increases in CPu and Cg in WT and KO animals at i.v. doses of
0.2, 0.07, and 0.007 mg/kg (Supplementary Fig. 1).
The time course of decay of the initial BOLD signal decrease
following apomorphine was estimated by fitting an exponential
function to individual traces, starting from the negative peak of
the response (y = A × e[−λ×t], where y is the BOLD signal
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with nonspecific binding autoradiograms, and the mean specific binding
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amplitude at time t, A is the BOLD signal amplitude at the start of
the fit, λ is the exponential decay constant, and t is time in sec-
onds). The response decay rate was significantly slower in CPu
ofKO animals, as compared toWT (WT; 0.028 ± 0.005 s−1, KO;
0.014 ± 0.004 s−1, p = 0.045, Student’s t-test; Fig. 5), whereas in
Cg, decay rates were similar between genotypes (WT;
0.018 ± 0.004 s−1, KO; 0.015 ± 0.004, p = 0.650; Fig. 5). On
color-coded maps for intervals of 600 to 900 s (i.e., 5 to 10 min
post-apomorphine; covering much of the decay time course in
CPu) the prolonged negative response component, i.e., a slower
decay of the response in the KO CPu, is represented by blue
clusters, in contrast to red clusters for WT animals, in which the
negative BOLD response component appeared shorter (Fig. 3
middle panel). While there was no significant difference in re-
sponse decay time course between genotypes in Cg,WTanimals
showed more positive changes in this region compared to
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or without pretreatment with
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n = 15; WT + Eticlo + Apo,
n = 11; KO + Eticlo + Apo,
n = 11. bMean BOLD signal
change in the respective brain
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indicated by shading in (a); light
red, 0–5 min after Apo injection;
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revealed a significant main effect
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pairwise comparisons detected
significant differences between
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Control traces showing BOLD
signal changes upon i.v.
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(n = 2). Brain regions correspond
to those in (a). All data are given
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KO during the 600–900 s interval (Fig. 3 middle panel),
reflecting the positive response component in Cg ofWTanimals,
as noted above.
Systemic cardiovascular effects of apomorphine treatment
In bench-top experiments performed on animals undergoing
the same protocol of anesthesia and artificial ventilation as
during the fMRI scans, upon i.v. injection of 0.2 mg/kg
apomorphine, heart rate decreased transiently from
576 ± 3 bpm in WT to 506 ± 61 bpm in KO mice during
5 min baseline prior to drug injection, to 469 ± 15 bpm in
WT and 495 ± 64 bpm in KO mice during the first 5 min
following drug injection. During the same intervals, pulse
distention displayed increases from an average of
16.9 ± 3.2 μm in WT and 16.7 ± 1.3 μm in KO mice,
to 55.7 ± 13.3 μm in WT and 90.7 ± 23.8 μm in KO mice.
O2 saturation increased from 94.5 ± 1.6% in WT and
93.3 ± 3.3% in KO to 96.3 ± 1.2% in WT and
97.4 ± 0.8% in KO (Fig. 6); the values returned to baseline
earlier in WT mice. None of the values were significantly
different between genotypes (not shown).
Discussion
Whereas previous studies have used beta-arrestin2 KO mice to
investigate dopaminergic functions, the putative effect of the KO
on the densities of dopaminergic markers has not been investi-
gated with the precision provided by quantitative autoradiogra-
phy. Using this approach, the present study found D1R, D2/3R,
DAT, and VMAT2 densities to be similar betweenWTand beta-
arrestin2 KO mice, suggesting that the KO does not alter the
expression levels of other components of the dopamine system.
In agreement with our [3H]raclopride data, Skinbjerg et al.
(2010) reported similar binding of the D2/3R PET radiotracers,
[18F] fallypride and [11C] methoxy-norpropylapomorphine, be-
tween WT and beta-arrestin2 KO mice.
Beta-arrestin2 has been implicated mainly downstream of
D2R, rather than D1R, activation (Beaulieu et al. 2005; Peterson
et al. 2015). However, in the present study, we chose to use the
non-selective dopamine agonist, apomorphine, since this li-
gand was used in behavioral experiments with beta-arrestin2
KO mice, where the KO animals displayed significantly re-
duced locomotor activity as compared to WT (Beaulieu et al.
2005). Pretreatment of mice with the D2R antagonist,
eticlopride, which has been previously used to probe the
-4
-3
-2
-1
0
1
0 300 600 900 1200 1500 1800 2100
-3
-2
-1
0
1
-3
-2
-1
0
1
0 300 600 900 1200 1500 1800 2100
a
b
WT - Apo KO - Apo
Time [s]
Δ
B
O
L
D
 [
%
]
Apo
0.00
0.01
0.02
0.03
0.04 *s[ 
etar yac
e
d 
e
s
n
o
p
s
e
R
-1
]
0.00
0.01
0.02
0.03
0.04
Apo
Caudate/Putamen Cingulate cortex
WT + Apo
KO + Apo
Time [s]
Fig. 5 Comparison of response
decay rates in caudate/putamen
(CPu) and cingulate cortex (Cg)
between WT and beta-arrestin2
KO mice. a Traces from WT and
KOmice (same data as in Fig. 4a)
showing BOLD signal changes
upon administration of
apomorphine (Apo; time point
indicated by red dashed lines).
Dotted black curves indicate fits
of exponential functions to the
data. b Estimated response decay
rates. Exponential functions were
fitted to individual BOLD signal
traces, as exemplified by the fits
to mean data in (a), to estimate
rates of decay of the response to
i.v. apomorphine. Traces were
excluded from the analysis in
cases where an exponential
function could not be fitted. CPu
WT, n = 9; CPu KO, n = 13; Cg
WT, n = 8; Cg KO, n = 11;
*p < 0.05; Student’s t-test. All
data are shown as mean ± SEM
2026 Psychopharmacology (2017) 234:2019–2030
involvement of D2/3R signaling in fMRI responses evoked by
pharmacological (Chen et al. 2005) and nociceptive stimulation
(Shih et al. 2009, 2012; Chen et al. 2013), prevented
apomorphine-induced BOLD signal changes in the studied
brain regions. This suggests that D2R activation was responsi-
ble for the apomorphine-induced BOLD signal changes, which
would be consistent with the low dose of apomorphine used in
the present study, which was selected to minimize cardiovas-
cular side effects, along with the 5–10-fold higher affinity of
apomorphine for D2R vs. D1R (Millan et al. 2002).
The observed BOLD signal responses to apomorphine
were negative in CPu, whereas in Cg, a smaller BOLD signal
decrease was followed by a positive response component in
WT, but not in KO animals. Both positive and negative
response components were abolished by eticlopride
pretreatment. Contrasting to the present findings, Ireland
et al. (2005) found striatal BOLD signal increases in response
to D2R agonist administration in rat, and Nguyen et al. (2000)
and Schwarz et al. (2006), studying the effects of 2 mg/kg
and 0.2 mg/kg apomorphine, respectively, on rat cerebral
blood volume (CBV) changes, reported signal increases in
striatum. Delfino et al. (2007) reported a positive BOLD sig-
nal change in rat striatum in response to 1.25 mg/kg apomor-
phine, as well as to a D1R-specific agonist, whereas no sig-
nificant response was observed after administration of a D2R-
selective agonist. However, several studies have reported
negative striatal CBV changes in response to D2R activation
in rat (Chen et al. 2005; Choi et al. 2006; Shih et al. 2009),
whereas D1R agonism increased- and D1R antagonism de-
creased CBV in the same brain region (Choi et al. 2006).
Similarly, Dixon et al. (2005) reported that positive BOLD
responses resulting from administration of the dopamine re-
leasing agent, amphetamine, were blocked by a D1R antago-
nist, whereas a D2R antagonist blocked BOLD signal chang-
es in brain regions which showed negative responses. Hence,
the weight of evidence suggests that D1R and D2R activation
elicits hemodynamic responses which are mainly opposite in
sign (Mandeville et al. 2013). The positive striatal BOLD and
CBV responses observed with apomorphine in previous re-
ports may thus reflect greater activation of D1R, relative to
D2R, than was achieved in the present study.
Indeed, whereas D1R and D2R are present at similar den-
sities in mouse, D1R density is relatively greater in rat, which
might explain discrepancies between species, and also why
dopamine-releasing agents such as amphetamine produce pos-
itive BOLD and CBV responses in rat striatum (Mandeville
et al. 2013). Similarly, recent fMRI studies employing
optogenetics to stimulate midbrain dopamine neuron activity
reported CBV and BOLD signal increases in rat striatum
(Decot et al. 2016; Ferenczi et al. 2016; Lohani et al. 2016).
Interestingly, recent data (Urs et al. 2016) indicate that
arrestin-biased D2R ligands are able to recruit beta-arrestin2
only in cortical, as opposed to striatal, brain regions, presum-
ably due to the higher expression of beta-arrestin2 in cortex,
and that activation of the arrestin pathway has excitatory ef-
fects, in contrast to G protein-dependent effects downstream
of D2R, which are in general inhibitory. Although inference
about neuronal excitation vs. inhibition cannot be made on
basis of the sign of BOLD signal changes (Lauritzen et al.
2012; Shih et al. 2009), the observations of Urs et al. (2016)
seem to agree with the present results, which suggest that the
positive component of the BOLD response to apomorphine in
Cg is beta-arrestin2-dependent and elicited via D2R
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stimulation. In an attempt to corroborate the origin of this
positive response component in Cg, we evaluated BOLD sig-
nal responses to the D2R ligand, UNC9994, which is a partial
agonist at beta-arrestin2 recruitment to the D2R, while being
unable to elicit G protein-dependent signaling through this
receptor (Allen et al. 2011). However, because BOLD signal
responses to UNC9994 appeared to be independent of beta-
arrestin2, we did not further investigate the actions of this
ligand in the present study. These arrestin-independent re-
sponses might reflect non-dopaminergic activity of
UNC9994; indeed, this ligand has been reported to be an
agonist at 5HT1A and 5HT2C receptors in vitro (Allen et al.
2011).
In CPu, but not in Cg, the rate of response decay (return of
the BOLD signal towards baseline) was slightly but signifi-
cantly slower in KO compared toWTanimals. The slower rate
of response decay in beta-arrestin2 KO mice would be in
agreement with the known role of beta-arrestin2 in terminat-
ing D2R signaling through G proteins, and in mediating D2R
internalization (Skinbjerg et al. 2009, 2010). However, the
difference in decay rates between KO and WT animals was
modest, suggesting a substantial contribution of additional
factors besides beta-arrestin2 to response termination. For ex-
ample, the pharmacokinetics of apomorphine in mouse brain
might also play an important role in shaping the response
decay rate. To address the impact of pharmacokinetics on
response time course, fMRI measurements would need to be
performed in parallel, or ideally, simultaneously, with PET
imaging using D2/3R–specific radiotracers. Applying this ap-
proach to beta-arrestin2 KO and WT mice, as recently sug-
gested by Sander et al. (2016), would enable the assessment
not only of the contribution of D2R occupancy, but also that of
receptor internalization, to the rate of decay of the
apomorphine-induced BOLD signal response. The ongoing
development of small animal imaging systems combining
these two modalities (Wehrl et al. 2014) is expected to make
this option more widely accessible in the near future.
The increases in O2 saturation and pulse distention and
decreases in heart rate observed in response to apomorphine
administration indicate that this drug exerts systemic cardio-
vascular effects also at the low dose employed in the present
study. The changes in O2 saturation, and in particular, pulse
distention, tended to be greater and longer lasting in KOmice,
although the differences vs. WT were not significant. Beta-
arrestin2 is expressed also in the cardiovascular system
(Lymperopoulos and Bathgate 2013), and the trend towards
greater and longer lasting systemic cardiovascular responses
to apomorphine in KOmice may thus be related to diminished
desensitization of the receptors mediating this response.
Blood pressure changes, which may override cerebral
blood flow autoregulation, can influence the BOLD signal
considerably (Gozzi et al. 2007; Wang et al. 2006). Kalisch
et al. (2005) reported evidence that in rats, a higher dose of
apomorphine (1 mg/kg, i.v.) elicited peripheral hypotensive
effects which correlated with striatal brain BOLD signal de-
creases. It is thus important to monitor systemic hemodynam-
ic parameters for effects of drug administration, in order to
assess whether any such changes may confound the fMRI
readout. However, it appears less likely that the BOLD signal
changes observed in response to apomorphine in the present
study are caused solely by such systemic effects, as the dom-
inating BOLD signal changes are opposite in sign (negative)
to what would be expected for an increase in pulse distention,
(a measure which correlates with blood pressure; Olivera
et al. 2010) and an increase in peripheral O2 saturation.
Nevertheless, given the vasoactive actions of dopamine re-
ceptor agonists, which may occur on systemic as well as on
local tissue level (Kalisch et al. 2005; Choi et al. 2006), a
contribution of such direct vascular drug effects to the mea-
sured BOLD signal changes cannot be excluded in the pres-
ent study, nor in previous fMRI studies of dopaminergic func-
tion (which often used higher doses of agonist).
Finally, the anesthetic used can interfere with fMRI re-
sponses. Several previous studies of the dopamine system used
halothane (e.g., Chen et al. 2005; Choi et al. 2006; Dixon et al.
2005; Ireland et al. 2005; Schwarz et al. 2006) whereas Chen
et al. (2013) and Shih et al. (2009); 2012) used alpha-chloral-
ose, and Delfino et al. (2007) and Kalisch et al. (2005) used
isoflurane. The volatile anesthetics, halothane and isoflurane,
are known to induce prominent vasodilation which may alter
cerebrovascular response characteristics, whereas alpha-
chloralose has been suggested to interfere with the dopamine
system in particular (Haensel et al. 2015; Mandeville et al.
2014). Thus, confounding effects of anesthesia are not possible
to exclude in the present investigation, nor in previous studies
in the field where anesthetics were used. However, when study-
ing drug-induced fMRI responses, the use of anesthesia is often
preferable to imaging of awake animals, which presents its own
set of problems including the increased risk for motion-induced
artifacts and changes in physiological parameters such as
breathing rate (Mandeville et al. 2014), especially when admin-
istering dopaminergics and other drugs which might be expect-
ed to stimulate motor activity and autonomic functions.
In conclusion, the present study found prolonged D2R-de-
pendent BOLD response decay rates in CPu in beta-arrestin2
KO animals, which might reflect impaired D2R desensitiza-
tion, consistent with the known role of beta-arrestin2 in termi-
nating G protein-dependent signaling by this receptor.
Furthermore, a positive BOLD response component, apparent-
ly dependent on beta-arrestin2 signaling downstreamD2R, was
observed in Cg, but not in CPu. This response component may
represent the cortex-specific excitatory effects recently report-
ed for the D2R-arrestin pathway. The present results may be
informative for further live imaging studies addressing signal-
ing and desensitization mediated via beta-arrestin2, e.g., in
animal models of psychiatric disease.
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